Safety, pharmacokinetics, and antiviral activity of a novel HIV antiviral, ABX464, in treatment-naive HIV-infected subjects in a phase 2 randomized, controlled study

by Steens J., Scherrer D., Gineste P., Barrett P., Khuanchai S., Winai R., Ruxrungtham K., Tazi J., Murphy R., Ehrlich H.
Published 2017